An antibacterial pre-coated plate and its preparation method

By synergistically combining esterase-responsive sustained-release microcapsules with topcoat materials, interconnected pores are formed, solving the antibacterial problem of pre-coated panels in dark and humid environments, achieving long-lasting and environmentally friendly antibacterial effects, suitable for home appliances and other scenarios.

CN123063064APending Publication Date: 2026-11-10JIANGSU LIBA ENTERPRISE JOINT STOCK
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202611073430.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-20
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing pre-coated panels have poor antibacterial effects in dark and humid environments, and traditional antibacterial agents have problems such as nano-silver agglomeration, silver ion leaching pollution, and light dependence, which cannot meet the long-term antibacterial needs of home appliances.

Method used

By employing the synergistic effect of esterase-responsive sustained-release microcapsules and topcoat materials, interconnected pores are formed through microphase separation, enabling the targeted release of antibacterial drugs in the presence of fungi and stable retention in the absence of fungi. Biodegradable polylactic acid-glycolic acid copolymer is used as the microcapsule carrier to avoid heavy metal residues.

Benefits of technology

It achieves long-lasting antibacterial effect in dark and humid environments, avoiding the pollution risks of traditional antibacterial agents. It is suitable for built-in cabinets or backlit appliances and has environmentally friendly antibacterial properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123063064A_ABST
    Figure CN123063064A_ABST
Patent Text Reader

Abstract

This invention discloses an antibacterial pre-coated panel and its preparation method. The panel uses a zinc-based coated steel plate as the base layer, with a 15–150 μm thick UV-cured antibacterial topcoat layer. The topcoat consists of polyurethane acrylate, dipentaerythritol hexaacrylate, a photoinitiator, and esterase-responsive antibacterial drug microcapsules. Subsequent programmed temperature rise and fall induce microphase separation, forming interconnected pores. The technology provided by this invention enables drug release to be triggered only when fungi secrete esterases, and the microcapsules remain stably retained in a fungal-free environment, achieving long-lasting antibacterial effects. Furthermore, it requires no light stimulation and maintains high antibacterial efficiency even in dark and humid environments such as built-in cabinets and the backlighting surfaces of home appliances.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of environmentally friendly antibacterial pre-coated board technology, specifically relating to an environmentally friendly antibacterial pre-coated board with esterase-responsive antibacterial function and its preparation method. Background Technology

[0002] Pre-coated steel is a composite material made from cold-rolled steel, galvanized steel, or aluminum substrates through processes such as cleaning, chemical conversion, coating (primer + topcoat), and baking. Its core characteristic is "factory prefabrication"—the coating is completed in a strictly controlled industrial environment, resulting in more consistent quality compared to on-site spraying. Pre-coated steel also offers numerous other advantages:

[0003] Superior corrosion resistance: Ordinary galvanized steel sheets have a lifespan of about 5-8 years in humid environments, while pre-coated steel sheets, due to their multi-layer protection (substrate + coating + coating layer), can have a lifespan of 15-25 years (refer to ISO 12944 standard).

[0004] Cost savings of over 30%: Compared to on-site painting, pre-coated steel plates save on labor and construction time costs. Taking building exterior walls as an example, the overall cost per square meter is reduced by approximately 40 yuan (data source: "China Coated Steel Sheet and Strip Industry Analysis Report").

[0005] Excellent environmental performance: Water-based or powder coatings are used, and VOC emissions are <50g / m² (as required by national standard GB 30981-2020), which is far lower than the 120g / m² of traditional oil-based paints.

[0006] Diverse color options: More than 2,000 standard color codes are available through PVDF (polyvinylidene fluoride) or PE (polyester) coating, and the color retention is more than 10 years without fading.

[0007] According to data from the China Iron and Steel Association, the annual output of pre-coated steel sheets in China exceeded 12 million tons in 2022. Of this, about 60% was used in the construction industry (such as steel structure workshops and curtain walls), 30% was used in home appliances (refrigerator and air conditioner casings), and the remaining 10% was used in special fields such as automotive interiors.

[0008] With the improvement of living standards, more and more families own more home appliances. However, some appliances, such as washing machines, refrigerators, and air conditioners, are often kept in dark, high-humidity indoor environments, creating a breeding ground for mold. Large amounts of mold grow on air conditioner vents, the back panels and bottoms of washing machines and refrigerators, causing the products to turn black and affecting indoor air quality. From a microbiological perspective, dark and damp environments are suitable for the growth of various molds, such as Aspergillus and Penicillium. Their spores are spread indoors with the airflow when the air conditioner is running. Mold not only damages the appearance of home appliances and emits odors, but its spores and secondary metabolites (such as aflatoxin and ochratoxin) can also induce health problems such as allergies and asthma, becoming a new source of secondary indoor pollution.

[0009] In the past, the outer shell or inner liner of home appliances mostly used ordinary hydrophilic pre-coated steel plates. The organic coating only served a decorative and corrosion-resistant function and had no inhibitory effect on fungi. Therefore, pre-coated plates with antibacterial properties have become a research hotspot for product upgrades.

[0010] Currently, the mainstream sterilization methods for pre-coated panels, such as patents CN101537724A, CN107962835A, and CN201405550Y, mainly involve mixing silver ions (including nano-silver) into the coating, releasing the silver ions for sterilization after coating and curing. However, this method suffers from several drawbacks: nano-silver tends to agglomerate, reducing coating adhesion; silver ions can also cause yellowing and loss of gloss in the coating; excessive silver ion leaching can also be cytotoxic, and the waste solution can pollute the environment, causing heavy metal contamination.

[0011] Patent CN218714595U discloses a technique that incorporates semiconductor nanoparticles such as TiO2 into a coating, which, upon excitation by ultraviolet light, reacts with water and oxygen on the coating surface to generate active oxygen for sterilization. However, this pre-coated panel relies on light-induced sterilization, but home appliances are located indoors where visible light activity is low, making it unsuitable for appliances located in dark areas or embedded in cabinets.

[0012] Patent CN116220296A discloses a method of directly mixing organic antibacterial agents such as organosilicon quaternary ammonium salts into a coating for sterilization through leaching. However, quaternary ammonium salts are hydrophilic and continue to dissolve in humid environments, resulting in the absence of effective antibacterial components in the later coating, which cannot meet the long-term antibacterial requirements of home appliances.

[0013] Therefore, in view of the shortcomings of the existing technology, there is an urgent need to develop an environmentally friendly, antibacterial pre-coated board that is environmentally friendly, has long-lasting antibacterial properties, and is suitable for embedded cabinet or backlit home appliances. Summary of the Invention

[0014] To address the problems of the existing technologies, the inventors, through extensive experimental research, discovered that preparing antibacterial drugs into esterase-responsive sustained-release microcapsules, which work synergistically with topcoat materials and are cured through gradient temperature rise and fall, can induce the formation of interconnected pores with specific pore sizes. This effectively solves the defects of the existing technologies and achieves an intelligent antibacterial effect of "targeted drug release when fungi are present and stable retention when fungi are absent." This achieves the goals of environmentally friendly, long-lasting antibacterial properties and suitability for dark and humid environments.

[0015] This invention is achieved through the following means:

[0016] The present invention provides an antibacterial pre-coated panel, comprising a base layer and an antibacterial paint layer containing esterase-responsive antibacterial drug microcapsules.

[0017] In one aspect, the present invention provides an antibacterial pre-coated panel, comprising a base layer and an antibacterial topcoat layer:

[0018] a) The antibacterial topcoat layer is composed of polyurethane acrylate, dipentaerythritol hexaacrylate, photoinitiator, and esterase-responsive antibacterial drug microcapsules, and has interconnected pores with an average pore size of 30-150 nm; the most preferred interconnected pore size is 80 nm.

[0019] b) The base layer is a zinc-based coated steel plate.

[0020] Regarding the formation of interconnected pores, the inventors would like to point out that the interconnected pores of this invention are formed by the microphase separation of polyurethane acrylate and dipentaerythritol hexaacrylate, synergistically induced by antibacterial drug microcapsules. The core driving force for this microphase separation is the significant difference in the glass transition temperatures (Tg) of the two resins: on the one hand, the polyurethane acrylate is a polyether-type polyurethane acrylate with highly flexible molecular chain segments, forming a flexible continuous phase; on the other hand, dipentaerythritol hexaacrylate (DPHA), as a high-functionality acrylate monomer, has a high crosslinking density and a rigid molecular chain, forming a rigid dispersed phase. The difference in their glass transition temperatures leads to a decrease in thermodynamic compatibility during gradient curing. Utilizing the difference in glass transition temperatures and volume shrinkage rates between the two resin components, under the stress of programmed temperature rise and fall, microcracks are generated within the initially cured coating network and interconnected, thereby inducing the formation of a nanoscale interconnected pore structure. The antibacterial drug microcapsules (average particle size 55-100 nm) act as stress concentration points, assisting and regulating the formation and interconnection of pores.

[0021] Furthermore, the base layer is one of aluminum-zinc-magnesium plate, electro-galvanized plate, and hot-dip galvanized plate, with aluminum-zinc-magnesium plate being the preferred choice.

[0022] Furthermore, the thickness of the antibacterial topcoat layer is 15-150 μm, preferably 40-100 μm, and most preferably 60 μm.

[0023] Furthermore, the antibacterial topcoat layer is composed of the following components by weight percentage:

[0024] Polyurethane acrylate: 40%-73%;

[0025] Dipentaerythritol hexaacrylate: 13.5%-45%;

[0026] Photoinitiator: 2-4%;

[0027] Esterase-responsive antibacterial drug microcapsules: 3-15%, with the sum of the mass percentages of all components being 100%;

[0028] Furthermore, the mass ratio of polyurethane acrylate to dipentaerythritol hexaacrylate is 1-3:1.

[0029] Preferably, the mass ratio of polyurethane acrylate to dipentaerythritol hexaacrylate is 2:1. This ratio allows the coating to form a dense cross-linked network after UV curing while retaining appropriate flexibility, ensuring microcapsule encapsulation stability and imparting excellent salt spray and bending resistance to the topcoat. Experiments show that when the ratio is lower than 1:1, the cross-linking density is insufficient and the pores are too large; when it is higher than 3:1, the coating becomes brittle and the microcapsules are easily crushed. Therefore, 2:1 is the optimal balance point for both mechanical properties and controlled release performance. The optimal mass percentages of each component are: polyurethane acrylate 55%, dipentaerythritol hexaacrylate 27.5%, photoinitiator 3%, and esterase-responsive antibacterial drug microcapsules 14.5%.

[0030] Furthermore, the esterase-responsive antibacterial drug microcapsules are composed of the following components in weight percentage:

[0031] Antibacterial drugs: 15%-30%;

[0032] Fatty acid esters: 5%-20%;

[0033] Polylactic acid-glycolic acid copolymer: 50%-80%;

[0034] The mass ratio of the polylactic acid-hydroxyacetic acid copolymer to the fatty acid ester is 2.5-16:1.

[0035] Furthermore, the antibacterial drug is one or more of bifonazole, ciclopirox olamine, butenafine, amorolfine, clotrimazole, and nystatin; preferably bifonazole and ciclopirox olamine (mass ratio 1:1).

[0036] The fatty acid ester is one of glyceryl monostearate, glycol dispalmitate, and glyceryl tristearate; glyceryl monostearate is preferred.

[0037] The polylactic acid-glycolic acid copolymer has a lactic acid to glycolic acid molar ratio of 95 / 5, 90 / 10, or 85 / 15, and a molecular weight of 100-200 kDa. Preferably, the lactic acid to glycolic acid molar ratio is 90 / 10 and the molecular weight is 150 kDa.

[0038] On the other hand, the present invention also provides a method for preparing esterase-responsive antibacterial drug microcapsules for use in environmentally friendly antibacterial pre-coated panels, the method comprising the following steps:

[0039] Preparation of oil phase a:

[0040] Antibacterial drugs and fatty acid esters are added to dichloromethane or ethyl acetate and stirred at 200-400 rpm until completely dissolved to obtain oil phase a; preferably, the organic solvent is dichloromethane and the stirring speed is 300 rpm.

[0041] Preparation of oil phase b:

[0042] Polylactic acid-glycolic acid copolymer was dissolved in the same organic solvent as oil phase a to prepare a capsule material solution. The solution was stirred at 200-400 rpm for 1-2 hours until completely dissolved. Oil phase a was added to the capsule material solution and stirred and ultrasonically dispersed for 0.5-1 hours with an ultrasonic power of 80-150 W and a frequency of 20-40 kHz to obtain oil phase b. Preferably, the capsule material solution concentration was 25 g / L, the stirring speed was 300 rpm, the stirring time was 1.5 hours, the ultrasonic dispersion time was 0.7 hours, the ultrasonic power was 120 W, and the frequency was 30 kHz.

[0043] Preparation of primary emulsion:

[0044] Prepare a 0.5-2 wt% polyvinyl alcohol aqueous phase. Add oil phase b to the aqueous phase at a mass ratio of 1:3-5 and shear at 8000-15000 rpm for 5-15 min to form an O / W primary emulsion. Preferably, the concentration of the polyvinyl alcohol aqueous phase is 1.2 wt%, the mass ratio of oil phase b to aqueous phase is 1:4, the high-speed shearing speed is 12000 rpm, and the shearing time is 10 min.

[0045] Fine emulsion and curing:

[0046] Immediately transfer the primary emulsion to a water bath at 30-40℃, stir at 200-400 rpm, and evaporate the organic solvent under reduced pressure of 20-25 kPa for 3-5 hours to solidify into capsules; preferably, the water bath temperature is 35℃, the stirring speed is 300 rpm, the reduced pressure is 23 kPa, and the evaporation time is 4 hours.

[0047] Freeze-drying:

[0048] The obtained microcapsules were washed with purified water by centrifugation at a speed of 12000-15000 r / min for 15-20 min each time, and the washing was repeated 3 times.

[0049] After washing, the microcapsules were dispersed in purified water to a concentration of 10-30 wt%, and then freeze-dried according to the following parameters:

[0050] Pre-freeze at -50℃ for 3-5 hours; perform a single sublimation drying at -5℃ for 10-15 hours, with vacuum controlled at 5-15 Pa; perform a second drying at 25℃ for 8-15 hours, with vacuum controlled at 1-5 Pa.

[0051] Antibacterial drug microcapsules with an average particle size of 55-100 nm, an encapsulation efficiency of ≥80%, and esterase-responsive drug release properties were obtained. The optimal average particle size was 80 nm.

[0052] Thirdly, the present invention provides a method for preparing an environmentally friendly antibacterial pre-coated board, characterized by comprising the following preparation steps:

[0053] Paint preparation:

[0054] Photoinitiator and antibacterial drug microcapsules are dispersed in polyurethane acrylate and dipentaerythritol hexaacrylate, and stirred at 300-500 rpm for 20-30 min to obtain a uniformly dispersed UV-curable coating.

[0055] Coating application:

[0056] The coating is applied to a cleaned, chemically converted, and primed substrate surface using roller coating, spraying, or doctor blade coating methods. It is then irradiated with ultraviolet light with a peak wavelength of 365nm and a cumulative energy density of 500-800mJ / cm² for 30-60 seconds to complete the initial curing. Preferably, the coating method is roller coating (suitable for industrial continuous production), with a cumulative energy density of 650mJ / cm² and an ultraviolet light irradiation time of 40 seconds.

[0057] Paint curing:

[0058] After initial curing, a programmed temperature rise is initiated in the drying tunnel, increasing the temperature to 80-90℃ at a rate of 5-10℃ / min and maintaining it for 0.5-2 hours. Then, a cooling program is initiated, decreasing the temperature to room temperature at a rate of 2-5℃ / min. During both the temperature rise and cooldown processes, air circulation is maintained within the drying tunnel, with a wind speed controlled at 0.3-1.0 m / s. This utilizes the difference in glass transition temperature to induce microphase separation, forming a topcoat layer with interconnected pores and an average pore size of 30-150 nm. Preferably, the programmed temperature rise rate is 7℃ / min, the curing temperature is 85℃, the holding time is 1 hour, the cooling rate is 3.5℃ / min, and the air circulation wind speed is 0.6 m / s.

[0059] The beneficial effects achieved by this invention are as follows:

[0060] 1. This invention utilizes "esterase-responsive microcapsules + interconnected pores" technology to achieve drug release triggered only when fungi secrete esterases, ensuring stable retention of the microcapsules in fungal-free environments and achieving long-lasting antibacterial effects. Furthermore, it requires no light stimulation and maintains high antibacterial efficacy even in dark and humid environments such as built-in cabinets and the backlighting surfaces of home appliances.

[0061] 2. The microcapsule carrier of the present invention uses biodegradable polylactic acid-glycolic acid copolymer (PLGA), and the antibacterial component is selected from low-toxicity drugs. It has no heavy metal residues and no cell accumulation toxicity, avoiding water pollution caused by traditional silver-based antibacterial agents, and achieving green and environmentally friendly results.

[0062] 3. The preparation process provided by this invention is stable and controllable, and is suitable for industrial production. Attached Figure Description

[0063] Figure 1 Particle size distribution of microcapsule DLS in Example 1

[0064] Figure 2 Particle size distribution of microcapsule DLS in Example 2

[0065] Figure 3 The particle size distribution of the microcapsule DLS in Example 3 is shown. Detailed Implementation

[0066] The following description illustrates exemplary embodiments of the present invention, including various details to aid understanding. These should be considered merely exemplary. Therefore, those skilled in the art will recognize that various changes and modifications can be made to the embodiments described herein without departing from the scope and spirit of the invention. Similarly, for clarity and brevity, descriptions of well-known functions, operations, and structures are omitted in the following description.

[0067] Unless otherwise defined, the technical and scientific terms used in this specification have the same meaning as commonly understood by one of ordinary skill in the art. While similar or identical methods and materials may be applied in experimental or practical applications, the present invention describes materials and methods hereinafter. In case of conflict, the definitions included herein shall prevail.

[0068] Example 1

[0069] This embodiment provides an optimal implementation of an antibacterial pre-coated plate, the preparation process of which includes two steps: preparation of esterase-responsive antibacterial drug microcapsules and preparation of an environmentally friendly antibacterial pre-coated plate, as detailed below:

[0070] I. Raw Material Preparation

[0071] Antibacterial drug: Bifonazole (purity ≥98%, purchased from Shanghai Yuanye Biotechnology Co., Ltd.);

[0072] Fatty acid esters: Glyceryl monostearate (purity ≥99%, purchased from Sinopharm Chemical Reagent Co., Ltd.);

[0073] Polylactic acid-glycolic acid copolymer (PLGA): Lactic acid to glycolic acid molar ratio 90 / 10, molecular weight 150kDa (purchased from Jinan Daigang Bioengineering Co., Ltd.).

[0074] Organic solvent: dichloromethane (analytical grade, purchased from Tianjin Kemeo Chemical Reagent Co., Ltd.);

[0075] Emulsifier: Polyvinyl alcohol (PVA, degree of polymerization 1750±50, purchased from Aladdin Reagent Co., Ltd.);

[0076] Resin system: polyurethane acrylate (PUA, Tg=-35℃, purchased from Changxing Chemical Industry Co., Ltd.)

[0077] Dipentaerythritol hexaacrylate (DPHA, Tg=93℃, purchased from Sartamer).

[0078] Photoinitiator: 1173 (2-hydroxy-2-methyl-1-phenyl-1-propanone, purity ≥99%, purchased from BASF).

[0079] Base layer: Aluminum zinc magnesium plate (coating weight 150g / m², plate thickness 0.5mm, purchased from Baowu Steel Group Co., Ltd.);

[0080] Auxiliary material: purified water (conductivity ≤10μS / cm).

[0081] II. Preparation of esterase-responsive antibacterial drug microcapsules

[0082] Preparation of oil phase a:

[0083] Accurately weigh 2.2g of bifonazole and 1.0g of glyceryl monostearate, add them to 1000mL of dichloromethane to make the total concentration of drugs and fatty acid esters 3.2g / L, place them on a magnetic stirrer and stir at 300rpm for 30min until the raw materials are completely dissolved to obtain a clear and transparent oil phase a.

[0084] Preparation of oil phase b:

[0085] Weigh 6.8g of PLGA and dissolve it in 1000mL of dichloromethane to prepare a capsule material solution with a concentration of 6.8g / L. Stir at 300rpm for 1.5h until completely dissolved. Slowly add the above oil phase a to the capsule material solution, continue stirring and start the ultrasonic disperser, set the ultrasonic power to 120W and the frequency to 30kHz, disperse for 0.7h to obtain a uniform oil phase b (appearance as a light blue emulsion).

[0086] Preparation of primary emulsion:

[0087] Weigh 12g of polyvinyl alcohol, add it to 1000mL of purified water, heat to 60℃ and stir to dissolve. After cooling to room temperature, a 1.2wt% PVA aqueous phase is obtained. According to the mass ratio of oil phase b to aqueous phase 1:4, 200g of oil phase b is slowly added to 800g of PVA aqueous phase. Start the high-speed shear machine and shear at 12000rpm for 10min to form a uniform O / W primary emulsion.

[0088] Fine emulsion and curing:

[0089] The initial emulsion was immediately transferred to a 35°C constant temperature water bath and stirred at 300 rpm. At the same time, the pressure reduction device was turned on and the pressure was controlled at 23 kPa. The organic solvent was evaporated for 4 hours. During this period, the emulsion was observed to gradually thicken and solidify into capsules to obtain a microcapsule suspension.

[0090] Freeze-drying:

[0091] The microcapsule suspension was transferred to centrifuge tubes and centrifuged at 13500 r / min for 17 min. The supernatant was discarded, and purified water was added for repeated washing three times. After washing, the microcapsules were dispersed in purified water and the concentration was adjusted to 20 wt%. The microcapsules were then transferred to a freeze dryer and freeze-dried according to the following parameters: pre-freezing at -50℃ for 4 h → sublimation drying at -5℃ for 13 h (vacuum 10 Pa) → secondary drying at 25℃ for 11 h (vacuum 3 Pa). The freeze-dried microcapsules were collected and appeared as a white, loose powder.

[0092] III. Preparation of Environmentally Friendly Antibacterial Pre-coated Panels

[0093] Primary pretreatment:

[0094] The aluminum-zinc-magnesium plate was sequentially subjected to alkaline washing (5wt% sodium hydroxide solution, 50℃, 5min), acid washing (1wt% hydrochloric acid solution, room temperature, 3min), and water washing until neutral. Then, it underwent chemical conversion treatment (chromate passivation, film weight 80mg / m²). Finally, it was coated with epoxy primer (10μm thickness) and dried (120℃, 1h) for later use.

[0095] Paint preparation:

[0096] Weigh out 55% polyurethane acrylate, 27.5% dipentaerythritol hexaacrylate, 3% photoinitiator, and 14.5% esterase-responsive antibacterial microcapsules by mass percentage, for a total mass of 1000g; add the photoinitiator and microcapsules to the resin mixture in sequence, place it on a stirrer and stir at 400rpm for 25min to obtain a uniformly dispersed UV-curable coating.

[0097] Coating application:

[0098] The above coating was applied to the pretreated substrate surface by roller coating, with the roller coating pressure adjusted to 0.3 MPa and the wet film thickness controlled to 80 μm. Then, it was irradiated with a UV curing machine (peak wavelength 365 nm, cumulative energy density 650 mJ / cm², irradiation time 40 s) to complete the initial curing.

[0099] Paint curing:

[0100] The pre-cured board was immediately sent into the drying tunnel and the temperature program was started: the temperature was increased to 85℃ at a rate of 7℃ / min and maintained for 1 hour; then the temperature was reduced to room temperature at a rate of 3.5℃ / min, and the air circulation speed in the drying tunnel was controlled at 0.6m / s; after curing, an environmentally friendly antibacterial pre-coated board with an antibacterial topcoat layer thickness of 60μm was obtained.

[0101] Example 2: Preparation of small-particle-size esterase-responsive antibacterial drug microcapsules

[0102] I. Raw Material Preparation

[0103] Same as Example 1;

[0104] The resin system, photoinitiator, substrate, and purified water are not involved.

[0105] II. Preparation of esterase-responsive antibacterial drug microcapsules

[0106] Preparation of oil phase a:

[0107] Same as Example 1.

[0108] Preparation of oil phase b:

[0109] Same as Example 1.

[0110] Preparation of primary emulsion:

[0111] Weigh 12g of polyvinyl alcohol, add 1000 mL of purified water, dissolve at 60 ℃ and cool to obtain 1.2 wt% PVA aqueous phase; slowly add 200g of oil phase b to 1000g of PVA aqueous phase (oil-water mass ratio 1:5), and shear at 15000rpm for 15min using a high-speed shear machine to form O / W primary emulsion.

[0112] Fine emulsion and curing:

[0113] The primary emulsion was immediately transferred to a 30°C water bath, stirred at 400 rpm, and the organic solvent was evaporated under reduced pressure of 20 kPa for 3 hours to solidify into capsules.

[0114] Freeze-drying:

[0115] Same as Example 1.

[0116] Example 3: Preparation of large-particle-size esterase-responsive antibacterial drug microcapsules

[0117] I. Raw Material Preparation

[0118] Same as Example 1;

[0119] The resin system, photoinitiator, substrate, and purified water are not involved.

[0120] II. Preparation of esterase-responsive antibacterial drug microcapsules

[0121] Preparation of oil phase a:

[0122] Same as Example 1.

[0123] Preparation of oil phase b:

[0124] Same as Example 1.

[0125] Preparation of primary emulsion:

[0126] Weigh 12g of polyvinyl alcohol, add 1000 mL of purified water, dissolve at 60℃ and cool to obtain 1.2 wt% PVA aqueous phase; slowly add 200g of oil phase b to 600g of PVA aqueous phase (oil-water mass ratio 1:3), and shear at 8000rpm for 5min using a high-speed shear machine to form an O / W primary emulsion.

[0127] Fine emulsion and curing:

[0128] The initial emulsion was immediately transferred to a 40°C water bath, stirred at 200 rpm, and the organic solvent was evaporated under reduced pressure of 25 kPa for 5 hours to solidify into capsules.

[0129] Freeze-drying:

[0130] Same as Example 1.

[0131] Example 4: Preparation of Environmentally Friendly Antibacterial Pre-coated Panels with Small Porosity

[0132] I. Raw Material Preparation

[0133] The antibacterial drug, fatty acid ester, polylactic acid-glycolic acid copolymer (PLGA), organic solvent, and emulsifier are used in the small-particle-size esterase-responsive antibacterial drug microcapsules prepared in Example 2;

[0134] The resin system, photoinitiator, base layer, and purified water are the same as in Example 1.

[0135] II. Preparation of esterase-responsive antibacterial drug microcapsules

[0136] The sample prepared in Example 2 was used directly.

[0137] III. Preparation of Environmentally Friendly Antibacterial Pre-coated Panels

[0138] Primary pretreatment:

[0139] Same as Example 1.

[0140] Paint preparation:

[0141] Weigh 2.0 g of photoinitiator 1173 and 13.0 g of the microcapsules prepared in Example 2, disperse them in 55.0 g of polyurethane acrylate and 20.0 g of dipentaerythritol hexaacrylate, stir at 400 rpm for 25 min to obtain a UV-curable coating.

[0142] Coating application:

[0143] The above coating was applied to the pretreated substrate surface by roller coating, the coating pressure was adjusted to 0.3MPa, the wet film thickness was controlled to 80μm, and the substrate was irradiated with 600 mJ / cm² UV light at 365nm for 40s to complete the initial curing.

[0144] Paint curing:

[0145] The pre-cured board is immediately sent into the drying tunnel and the temperature program is started: the temperature is increased to 80°C at a rate of 5°C / min and maintained for 0.5h; then the temperature is reduced to room temperature at a rate of 5°C / min. The air circulation in the drying tunnel adopts a high wind speed of 1.0m / s to quickly remove the solvent and inhibit the formation of macropores. After curing, an environmentally friendly antibacterial pre-coated board with an antibacterial topcoat layer thickness of about 60μm is obtained.

[0146] Example 5: Preparation of a large-pore environmentally friendly antibacterial pre-coated plate

[0147] I. Raw Material Preparation

[0148] The antibacterial drug, fatty acid ester, polylactic acid-glycolic acid copolymer (PLGA), organic solvent, and emulsifier are used in the large-particle-size esterase-responsive antibacterial drug microcapsules prepared in Example 3;

[0149] The resin system, photoinitiator, base layer, and purified water are the same as in Example 1.

[0150] II. Preparation of esterase-responsive antibacterial drug microcapsules

[0151] The sample prepared in Example 3 was used directly.

[0152] III. Preparation of Environmentally Friendly Antibacterial Pre-coated Panels

[0153] Primary pretreatment:

[0154] Same as Example 1.

[0155] Paint preparation:

[0156] Weigh 2.0g of photoinitiator 1173 and 13.0g of the microcapsules prepared in Example 3, disperse them in 55.0g of polyurethane acrylate and 20.0g of dipentaerythritol hexaacrylate, stir at 400rpm for 25min to obtain UV-curable coating.

[0157] Coating application:

[0158] The above coating was applied to the pretreated substrate surface by roller coating, the coating pressure was adjusted to 0.3MPa, the wet film thickness was controlled to 80μm, and the substrate was irradiated with 800mJ / cm² UV light at 365nm for 60s to complete the initial curing.

[0159] Paint curing:

[0160] The pre-cured board was immediately sent into the drying tunnel and the temperature program was started: the temperature was increased to 90°C at a rate of 10°C / min and maintained for 2 hours; then the temperature was reduced to room temperature at a rate of 2°C / min. The air circulation in the drying tunnel adopted a low wind speed of 0.3m / s to prolong the solvent retention and fully promote microphase separation. After curing, an environmentally friendly antibacterial pre-coated board with an antibacterial topcoat layer thickness of 60μm was obtained.

[0161] Examples 6-7: Preparation of Environmentally Friendly Antibacterial Pre-coated Panels of Different Thicknesses

[0162] I. Raw Material Preparation

[0163] Same as Example 1.

[0164] II. Preparation of esterase-responsive antibacterial drug microcapsules

[0165] Same as Example 1.

[0166] III. Preparation of Environmentally Friendly Antibacterial Pre-coated Panels

[0167] Primary pretreatment:

[0168] Same as Example 1.

[0169] Paint preparation:

[0170] Same as Example 1.

[0171] Coating application:

[0172] Except for the thickness of the wet film, everything else is the same as in Example 1.

[0173] The specific control of wet thickness is as follows:

[0174] Example Thickness (μm) Example 6 25 Example 7 180

[0175] Paint curing:

[0176] Except for the film thickness, everything else is the same as in Example 1.

[0177] The wet film shrinks after curing and drying; the specific thickness of the antibacterial topcoat layer is as follows:

[0178] Example Thickness (μm) Example 6 15 Example 7 150

[0179] Example 8: Preparation of environmentally friendly antibacterial pre-coated panels with different antibacterial drugs

[0180] I. Raw Material Preparation

[0181] Except for the antibacterial drugs, everything else is the same as in Example 1.

[0182] Antibacterial drug: Bifonazole (purity ≥98%, purchased from Shanghai Yuanye Biotechnology Co., Ltd.)

[0183] Ciclopirox olamine (purity ≥99%, sourced from Hubei Keyi Pharmaceutical Co., Ltd.)

[0184] II. Preparation of esterase-responsive antibacterial drug microcapsules

[0185] Same as Example 1. Except that bifonazole is replaced with a 1:1 mixture of bifonazole and ciclopirox olamine.

[0186] III. Preparation of Environmentally Friendly Antibacterial Pre-coated Panels

[0187] Primary pretreatment:

[0188] Same as Example 1.

[0189] Paint preparation:

[0190] Same as Example 1.

[0191] Coating application:

[0192] Same as Example 1.

[0193] Paint curing:

[0194] Same as Example 1.

[0195] in conclusion:

[0196] The pre-coated plates prepared in this set of examples contain bifonazole and ciclopirox olamine as antibacterial agents. Bifonazole has extremely strong antibacterial activity against Trichophyton spp., and ciclopirox olamine has extremely strong antibacterial activity against Candida spp. The two are combined in a 1:1 mass ratio to cover the full spectrum of common pathogens; moreover, the two have a synergistic effect, which can reduce the minimum inhibitory concentration of a single drug.

[0197] Experimental Example 1: Assay of Esterase-Responsive Antibacterial Drug Microcapsules

[0198] Microcapsule size determination

[0199] Measurement method: Particle size and distribution were determined using wet dynamic light scattering (DLS).

[0200] Instrument: Malvern;

[0201] Dispersion medium: ultrapure water (refractive index RI = 1.330, viscosity 0.8872 cP, 25 °C);

[0202] Equilibrium temperature: 25.0 ℃;

[0203] Measurement location: 3.00mm;

[0204] Data analysis: The intensity distribution (Size Distribution by Intensity) is used, and the Z-average value and multimodal distribution results are obtained.

[0205] Take 100 mg of the sample microcapsules to be tested, add 50 mL of ultrapure water and ultrasonically disperse for 2 min. After filtering through a 0.45 µm filter membrane, measure according to the DLS method described above to obtain the results.

[0206] Encapsulation efficiency determination

[0207] Determination method: High performance liquid chromatography (HPLC)

[0208] Instrument: Agilent 1260 Infinity II high-performance liquid chromatograph (or equivalent), equipped with a UV detector;

[0209] Column: Agilent ZORBAX SB-C18, 4.6 × 250 mm, 5 μm;

[0210] Mobile phase: Acetonitrile: 0.05% trifluoroacetic acid aqueous solution = 75:25 (v / v);

[0211] Standard: Bifonazole reference standard (purity ≥98%);

[0212] Take 100 mg of the sample microcapsules to be tested, add 50 mL of encapsulation fluid (methanol:acetonitrile = 1:1), sonicate for 15 min, and filter through a 0.22 µm filter membrane; separately take an equal volume of microcapsules, add 20 mL of phosphate buffered saline (PBS, 0.01 mol / L, pH 7.4), vortex centrifuge, and collect the supernatant. Perform HPLC (253 nm, 1 mL / min) on both solutions, and calculate the total drug content and free drug content using the external standard method.

[0213] Encapsulation rate = (Total drug amount - Free drug amount) / Total drug amount × 100%, which gives the result.

[0214] Test results

[0215] The test results for each embodiment are as follows:

[0216] project Particle size (nm) Encapsulation rate (%) Example 1 (microcapsules) 78 93.5 Example 2 55 95.4 Example 3 101 93.4

[0217] in conclusion

[0218] Each embodiment exhibits a relatively high encapsulation effect; by adjusting the emulsion shear speed and time, esterase-responsive microcapsules of different particle sizes can be obtained in a controllable manner, and the encapsulation rate increases with the reduction of particle size, demonstrating the controllability of the process.

[0219] Experimental Example 2: Enzyme-triggered release verification

[0220] Grouping

[0221] Group A: PBS (enzyme-free)

[0222] Group B: PBS + Aspergillus niger lipase 2U / mL

[0223] Take 100 mg of the microcapsules from Example 1, add 20 mL of the corresponding medium, and place them on a constant temperature shaking bed at 37°C and 100 rpm in the dark. After 24 h, take a sample to determine the concentration of bifonazole and calculate the release rate.

[0224] result

[0225] 24-hour cumulative release: Group A 9%, Group B 74%.

[0226] in conclusion:

[0227] In group A, the small amount of drug released was mainly unencapsulated drug. In group B, the drug was released due to microcapsule hydrolysis triggered by a high concentration of fungal lipase. This confirms that lipases or keratinase produced during pathogenic fungal infection can hydrolyze fatty acid esters in the microcapsules, triggering microcapsule degradation and releasing most of the bifonazole, thus achieving targeted antibacterial action.

[0228] Experimental Example 3: Determination of Porosity and Salt Spray Resistance of Pre-coated Panels

[0229] Porosity determination method

[0230] The determination was made in accordance with GB / T 21650.2-2008 "Determination of pore size distribution and porosity of solid materials by mercury porosimetry and gas adsorption method - Part 2: Gas adsorption method".

[0231] Connectivity Pore Measurement

[0232] The main peak of the BJH desorption branch was determined according to GB / T 21650.2-2008; combined with SEM electron microscopy observation.

[0233] Salt spray resistance

[0234] The test was conducted in accordance with GB / T 1771-2021 "Determination of resistance to neutral salt spray of paints and varnishes".

[0235] Test results

[0236] project Porosity (%) Connecting pores (nm) 500h smoke (single-sided erosion / level) Example 1 8.2 82 0.8 mm / 1 Example 4 5.9 38 0.5 mm / 1 Example 5 11.1 145 1.1 mm / 1 Example 6 9.8 102 0.9 mm / 1 Example 7 8.0 98 0.8 mm / 1 Example 8 7.9 80 0.7 mm / 1

[0237] in conclusion

[0238] The microphase separation topcoat of this invention has a uniform pore size distribution, a long salt spray penetration path, and a corrosion diffusion of <2mm after 500h. All embodiments show good salt spray resistance.

[0239] The pre-coated panels obtained in Examples 1 and 4-8 above were subjected to antibacterial performance tests (test strains: Aspergillus niger, Aspergillus spp., etc.) in accordance with GB / T 21866-2008 standard. After 28 days, the anti-mold level was 0 for all of them.

[0240] After the board was stored in an environment of 40℃ and 95%RH for 180 days, its antibacterial properties did not decrease significantly.

[0241] The pre-coated panel provided by this invention has excellent, long-lasting and intelligently responsive antibacterial properties.

Claims

1. An antibacterial pre-coated panel, comprising a base layer and an antibacterial topcoat layer, characterized in that, a) The antibacterial topcoat layer is composed of polyurethane acrylate, dipentaerythritol hexaacrylate, photoinitiator, and esterase-responsive antibacterial drug microcapsules, and has interconnected pores with an average pore size of 30-150 nm. b) The base layer is a zinc-based coated steel plate.

2. The antibacterial pre-coated panel according to claim 1, characterized in that, The zinc-based coated steel sheet is one of aluminum zinc magnesium sheet, electro-galvanized sheet, or hot-dip galvanized sheet.

3. The antibacterial pre-coated panel according to claim 1, characterized in that, The thickness of the antibacterial topcoat layer is 15-150 μm.

4. The antibacterial pre-coated panel according to claim 1, characterized in that, The antibacterial topcoat layer is composed of the following components by weight percentage: Polyurethane acrylate: 40%-73%; Dipentaerythritol hexaacrylate: 13.5%-45%; Photoinitiator: 2-4%; Esterase-responsive antibacterial drug microcapsules: 3-15%, with the sum of the mass percentages of all components being 100%; Furthermore, the mass ratio of polyurethane acrylate to dipentaerythritol hexaacrylate is 1-3:

1.

5. The antibacterial pre-coated panel according to claim 4, characterized in that, The esterase-responsive antibacterial drug microcapsules are composed of the following components by weight percentage: Antibacterial drugs: 15%-30%; Fatty acid esters: 5%-20%; Polylactic acid-glycolic acid copolymer: 50%-80%, total mass of capsule material is 100%; The mass ratio of the polylactic acid-hydroxyacetic acid copolymer to the fatty acid ester is 2.5-16:

1.

6. The antibacterial pre-coated panel according to claim 5, characterized in that, The antibacterial drug mentioned is one or more of bifonazole, ciclopirox olamine, butenafine, amorolfine, clotrimazole, and nystatin; The fatty acid ester is one of glyceryl monostearate, glycol dispalmitate, and glyceryl tristearate. The polylactic acid-glycolic acid copolymer has a lactic acid to glycolic acid molar ratio of 95 / 5, 90 / 10, or 85 / 15, and a molecular weight of 100-200 kDa.

7. A method for preparing esterase-responsive antibacterial drug microcapsules, used in the antibacterial pre-coated plate according to any one of claims 1-6, characterized in that, The method includes the following steps: Preparation of oil phase a: Add the antibacterial drug and fatty acid ester to dichloromethane or ethyl acetate, and stir at 200-400 rpm until completely dissolved to obtain oil phase a; Preparation of oil phase b: Polylactic acid-glycolic acid copolymer was dissolved in the same organic solvent as oil phase a to prepare a capsule material solution. The solution was stirred at 200-400 rpm for 1-2 hours until completely dissolved. Oil phase a was added to the capsule material solution and stirred and ultrasonically dispersed for 0.5-1 hours. The ultrasonic power was 80-150W and the frequency was 20-40kHz to obtain oil phase b. Preparation of primary emulsion: Prepare a 0.5-2wt% polyvinyl alcohol aqueous phase. Add oil phase b to the aqueous phase at a mass ratio of 1:3-5 and shear at 8000-15000 rpm for 5-15 minutes to form an O / W primary emulsion. Fine emulsion and curing: Immediately transfer the primary emulsion to a 30-40℃ water bath, stir at 200-400 rpm, evaporate the organic solvent under reduced pressure of 20-25 kPa for 3-5 hours, and solidify into capsules; Freeze-drying: The obtained microcapsules were washed with purified water by centrifugation at a speed of 12000-15000 r / min for 15-20 min each time, and the washing was repeated 3 times. After washing, the microcapsules were dispersed in purified water to a concentration of 10-30 wt%, and then lyophilized according to the following parameters: Pre-freeze at -50℃ for 3-5 hours; perform a single sublimation drying at -5℃ for 10-15 hours, with vacuum controlled at 5-15 Pa; perform a second drying at 25℃ for 8-15 hours, with vacuum controlled at 1-5 Pa. Antibacterial drug microcapsules with an average particle size of 55-100 nm, an encapsulation efficiency of ≥80%, and esterase-responsive drug release properties were obtained.

8. A method for preparing the antibacterial pre-coated plate according to any one of claims 1-6, characterized in that, Includes the following steps: Paint preparation: Photoinitiator and antibacterial drug microcapsules are dispersed in polyurethane acrylate and dipentaerythritol hexaacrylate, and stirred at 300-500 rpm for 20-30 min to obtain a uniformly dispersed UV-curable coating. Coating application: The coating is applied to the cleaned, chemically converted, and primed substrate surface using roller coating, spraying, or doctor blade coating methods. Then, it is irradiated with ultraviolet light with a peak wavelength of 365nm and a cumulative energy density of 500-800mJ / cm² for 30-60 seconds to complete the initial curing. Paint curing: After initial curing, the temperature is increased to 80-90℃ at a rate of 5-10℃ / min and maintained for 0.5-2 hours in the drying tunnel. Then, the cooling process is initiated, and the temperature is reduced to room temperature at a rate of 2-5℃ / min. During the temperature increase and decrease, air circulation is maintained in the drying tunnel, and the wind speed is controlled at 0.3-1.0m / s. The difference in glass transition temperature is used to induce microphase separation, forming a topcoat layer with interconnected pores and an average pore size of 30-150nm.

Citation Information

Patent Citations

  • Color coated steel plate with antibacterial function and production process thereof

    CN101537724A

  • Colorful precoating steel plate having antibiosis effect and production technology thereof

    CN107962835A

  • Color coated steel sheet with antibacterial layer

    CN201405550Y